Human Mesenchymal Stem Cells Reprogram Adult Cardiomyocytes Toward a Progenitor-like State Through Partial Cell Fusion and Mitochondria Transfer
Overview
Reproductive Medicine
Authors
Affiliations
Because stem cells are often found to improve repair tissue including heart without evidence of engraftment or differentiation, mechanisms underlying wound healing are still elusive. Several studies have reported that stem cells can fuse with cardiomyocytes either by permanent or partial cell fusion processes. However, the respective physiological impact of these two processes remains unknown in part because of the lack of knowledge of the resulting hybrid cells. To further characterize cell fusion, we cocultured mouse fully differentiated cardiomyocytes with human multipotent adipose-derived stem (hMADS) cells as a model of adult stem cells. We found that heterologous cell fusion promoted cardiomyocyte reprogramming back to a progenitor-like state. The resulting hybrid cells expressed early cardiac commitment and proliferation markers such as GATA-4, myocyte enhancer factor 2C, Nkx2.5, and Ki67 and exhibited a mouse genotype. Interestingly, human bone marrow-derived stem cells shared similar reprogramming properties than hMADS cells but not human fibroblasts, which suggests that these features might be common to multipotent cells. Furthermore, cardiac hybrid cells were preferentially generated by partial rather than permanent cell fusion and that intercellular structures composed of f-actin and microtubule filaments were involved in the process. Finally, we showed that stem cell mitochondria were transferred into cardiomyocytes, persisted in hybrids and were required for somatic cell reprogramming. In conclusion, by providing new insights into previously reported cell fusion processes, our data might contribute to a better understanding of stem cell-mediated regenerative mechanisms and thus, the development of more efficient stem cell-based heart therapies.
Therapeutic Potential of Adipose-Derived Regenerative Cells for Ischemic Diseases.
Che Y, Shimizu Y, Murohara T Cells. 2025; 14(5).
PMID: 40072072 PMC: 11898683. DOI: 10.3390/cells14050343.
Engineered mitochondria in diseases: mechanisms, strategies, and applications.
Li M, Wu L, Si H, Wu Y, Liu Y, Zeng Y Signal Transduct Target Ther. 2025; 10(1):71.
PMID: 40025039 PMC: 11873319. DOI: 10.1038/s41392-024-02081-y.
Hassanpour P, Sadeghsoltani F, Saghebasl S, Boroumand S, Khanicheragh P, Ahmadi Tafti S Stem Cell Res Ther. 2025; 16(1):54.
PMID: 39920826 PMC: 11806797. DOI: 10.1186/s13287-025-04193-w.
Mitochondrial dysfunction and Alzheimer's disease: pathogenesis of mitochondrial transfer.
Wei Y, Du X, Guo H, Han J, Liu M Front Aging Neurosci. 2025; 16:1517965.
PMID: 39741520 PMC: 11685155. DOI: 10.3389/fnagi.2024.1517965.
Lee S, Yu S, Kim I, Kang Y, Kim Y, Yeo J Int J Mol Sci. 2024; 25(23).
PMID: 39684495 PMC: 11641484. DOI: 10.3390/ijms252312783.